Pharvaris NV
PHVS
View Detailed Chart
26.420USD
+1.280+5.09%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.72BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.09%
5 Days
-2.33%
1 Month
+9.85%
6 Months
+24.45%
Year to Date
-4.79%
1 Year
+44.69%
View Detailed Chart
TradingKey Stock Score
No stock score available due to insufficient data.
Pharvaris NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pharvaris NV Info
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Ticker SymbolPHVS
CompanyPharvaris NV
CEOModig (Berndt B.A.E)
Websitehttps://pharvaris.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68999.440
-970.690 (-1.39%)
282.580
+22.390 (+8.61%)
2041.360
-10.370 (-0.51%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
